Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.
This video is part of the Independent Medical Education program entitled, 'Improving PBC outcomes by prioritising patients' needs'. This expert-led program will allow you to effectively evaluate treatment response in your patients, and make informed decisions on individualized patient management strategies, regarding therapy response, symptom management, clinical guidelines, and new advances in the PBC treatment landscape.
To learn more about the full program, visit pbc.ime.springerhealthcare.com
---
This program is made possible thanks to an independent educational grant from Ipsen.
